中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

883 records (took 0.069 seconds)

    DEVELOPMENT OF A C-REACTIVE PROTEIN MUTANT WITH IMPROVED THERAPEUTIC BENEFIT IN IMMUNE THROMBOCYTOPENIA AND LUPUS NEPHRITIS
    221.
    发明申请
    DEVELOPMENT OF A C-REACTIVE PROTEIN MUTANT WITH IMPROVED THERAPEUTIC BENEFIT IN IMMUNE THROMBOCYTOPENIA AND LUPUS NEPHRITIS 审中-公开
    在免疫性脑血管病和红斑狼疮中改善治疗效果的C-反应蛋白突变体的发展

    公开(公告)号：WO2009148566A2

    公开(公告)日：2009-12-10

    申请号：PCT/US2009/003338

    申请日：2009-06-02

    Applicant: STC.UNM ,  DU CLOS, Terry, W. ,  MOLD, Carolyn

    Inventor： DU CLOS, Terry, W. ,  MOLD, Carolyn

    IPC: A61K38/16 ,  A61P13/12 ,  A61P19/02

    CPC classification number: A61K38/1745 ,  C07K14/4737

    Abstract: The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the treatment of various disease states and conditions associated with SLE, including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with SLE will have an outbreak is an additional aspect of the present invention. The present invention relates to the use of mutant Y175L CRP or L176E CRP in the treatment of a number of disease states or conditions that occur secondary to systemic lupus SLE. The present invention also relates to the treatment of immune thrombocytopenic purpura. Pharmaceutical compositions are also disclosed based these mutant CRP molecules.

    Abstract translation: 本发明涉及使用由亮氨酸（Y175L CRP）代替酪氨酸175或用谷氨酸（L176E CRP）代替的亮氨酸176用于治疗与SLE有关的各种疾病状态和病症的突变型CRP分子， 包括皮肤（盘状）的狼疮，关节，肺和肾的系统性红斑狼疮，包括溶血性贫血和低淋巴细胞计数的血液学病症，淋巴结病和CNS作用，包括记忆丧失，癫痫发作和精神病，其他如本文另有公开。 在本发明的另一方面，降低与SLE相关的疾病状态或病症发生风险的患者将发生爆发的可能性是本发明的另外的方面。 本发明涉及突变型Y175L CRP或L176E CRP在治疗多发于系统性红斑狼疮SLE继发性疾病状态或病症中的应用。 本发明还涉及免疫性血小板减少性紫癜的治疗。 还公开了基于这些突变CRP分子的药物组合物。

    THERAPEUTIC ULTRASOUND TRANSDUCER CHIP WITH INTEGRATED ULTRASOUND IMAGER AND METHODS OF MAKING AND USING THE SAME
    222.
    发明申请
    THERAPEUTIC ULTRASOUND TRANSDUCER CHIP WITH INTEGRATED ULTRASOUND IMAGER AND METHODS OF MAKING AND USING THE SAME 审中-公开
    具有集成超声波成像器的治疗超声波传感器芯片及其制造和使用方法

    公开(公告)号：WO2009111351A2

    公开(公告)日：2009-09-11

    申请号：PCT/US2009/035601

    申请日：2009-02-27

    Applicant: STC.UNM ,  CHEN, Jingkuang

    Inventor： CHEN, Jingkuang

    IPC: A61N7/02

    CPC classification number: B06B1/0292

    Abstract: A therapeutic ultrasound device may include a substrate, at least one high power capacitive micromachined ultrasonic transducer, and at least one imager transducer comprising a capacitive micromachined ultrasonic transducer. The at least one high power capacitive micromachined ultrasonic transducer and the imager transducer may be monolithically integrated on the substrate.

    Abstract translation: 治疗性超声装置可以包括衬底，至少一个高功率电容微加工超声换能器，以及包括电容微加工超声换能器的至少一个成像器换能器。 至少一个高功率电容微加工超声换能器和成像器换能器可以单片地集成在基底上。

    HYDROPHOBIC ORGANIC-INORGANIC HYBRID SILANE COATINGS
    223.
    发明申请
    HYDROPHOBIC ORGANIC-INORGANIC HYBRID SILANE COATINGS 审中-公开
    疏水性有机 - 无机杂化硅烷涂层

    公开(公告)号：WO2008060883A2

    公开(公告)日：2008-05-22

    申请号：PCT/US2007/083630

    申请日：2007-11-05

    Applicant: STC.UNM ,  SHAH, Pratik B. ,  BRINKER, Jeffery C. ,  KOENE, Bryan E.

    Inventor： SHAH, Pratik B. ,  BRINKER, Jeffery C. ,  KOENE, Bryan E.

    IPC: B32B27/28 ,  C08G77/12

    CPC classification number: C08J7/04 ,  C08G77/14 ,  C08J2483/04 ,  C09D5/08 ,  C09D183/06 ,  C23C18/122 ,  C23C18/1254 ,  Y10T428/265 ,  Y10T428/31663

    Abstract: Exemplary embodiments provide compositions and devices for hydrophobic coatings, and methods for making them. The hydrophobic coating can be formed from a coating solution including, for example, organically modified silicates (ormosils) mixed with coupling agents. Specifically, a sol-gel solution can be formed including a plurality of alkoxy silane precursors that contains at least one glycidoxy alkoxy silane precursor. In an exemplary embodiment, the sol-gel solution can be a mixed sol-gel solution formed including a first solution mixed with a second solution. The first solution can include one or more alkoxy silane precursors, and the second solution can include at least one glycidoxy alkoxy silane precursor. A coupling agent can then be added and reacted with the (mixed) sol-gel solution forming the coating solution, which can be applied onto a substrate that needs to be protected from corrosion or from chemical and/or biological agents.

    Abstract translation: 示例性实施例提供用于疏水涂层的组合物和装置及其制造方法。 疏水涂层可以由包括例如与偶联剂混合的有机改性硅酸盐（ormosils）的涂料溶液形成。 具体而言，可以形成包含多个含有至少一种缩水甘油氧基烷氧基硅烷前体的烷氧基硅烷前体的溶胶 - 凝胶溶液。 在一个示例性实施方式中，溶胶 - 凝胶溶液可以是包含与第二溶液混合的第一溶液形成的混合溶胶 - 凝胶溶液。 第一溶液可以包括一种或多种烷氧基硅烷前体，并且第二溶液可以包含至少一种缩水甘油氧基烷氧基硅烷前体。 然后可以加入偶联剂并与形成涂层溶液的（混合的）溶胶 - 凝胶溶液反应，该溶液可以施加到需要防腐蚀的基材上或者从化学和/或生物试剂上施加。

    SYSTEM AND METHODS OF MELANOMA PREVENTION
    224.
    发明申请
    SYSTEM AND METHODS OF MELANOMA PREVENTION 审中-公开
    梅兰病预防系统与方法

    公开(公告)号：WO2008033548A2

    公开(公告)日：2008-03-20

    申请号：PCT/US2007/020100

    申请日：2007-09-17

    Applicant: STC.UNM ,  TIMMINS, Graham, S. ,  LUND, Leslie

    Inventor： TIMMINS, Graham, S. ,  LUND, Leslie

    IPC: A61K31/351 ,  A61P17/16 ,  A61Q17/04

    CPC classification number: A61K31/351 ,  A61K8/37 ,  A61K8/46 ,  A61K8/498 ,  A61K2800/782 ,  A61K2800/92 ,  A61Q17/04

    Abstract: Inhibiting the enzymic action of tyrosinase in the melanocyte prior to, during, or after ultraviolet (UV) radiation exposure, including over-exposure causing erythema, or sunburn, prevents the production of melanin and thereby melanoma. Melanoma can be prevented by using a tyrosinase inhibitor agent that inhibits the enzymic action of tyrosinase to prevent damage and/or death of melanocytes. The inhibitor agent can be applied to the skin or ingested.

    Abstract translation: 在紫外线（UV）辐射暴露（包括过度暴露引起红斑或晒伤）之前，期间或之后，在黑素细胞中抑制酪氨酸酶的酶作用可以防止黑色素和黑色素瘤的产生。 可以通过使用抑制酪氨酸酶的酶作用以防止黑素细胞的损伤和/或死亡的酪氨酸酶抑制剂来防止黑素瘤。 抑制剂可以施用于皮肤或摄取。

Patent Agency Ranking